Brief: Palisade Bio Announces First Subject Dosed In Phase 1 Clinical Study Of Pali-2108 For The Treatment Of Moderate-To-Severe Ulcerative Colitis
07/11/2024 13:59
Nov 7 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO ANNOUNCES FIRST SUBJECT DOSED IN PHASE 1
CLINICAL
STUDY OF PALI-2108 FOR THE TREATMENT OF MODERATE-TO-SEVERE
ULCERATIVE COLITIS (UC)
Source text: ID:nGNX55TlWz
Further company coverage: PALI.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing